Pelthos Therapeutics (PTHS) Stock: Buy, Sell, or Hold?
PTHS - Pelthos Therapeutics Inc.
$19.59
0.89 (4.76%)
▲
5d:
-3.31%
30d:
-16.71%
90d:
-24.42%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 12, 2026
20d
Get Alerted When PTHS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PTHS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PTHS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PTHS is currently trading at $19.59, which is considered oversold relative to its 30-day fair value range of $19.79 to $22.20.
Technical Outlook: Technically, PTHS is in a strong downtrend. Immediate support is located at $18.70, while resistance sits at $21.16. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: PTHS scores 91/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $51.71 (+164.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PTHS is in a strong downtrend. Immediate support is located at $18.70, while resistance sits at $21.16. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: PTHS scores 91/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $51.71 (+164.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$19.79 -
$22.20
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (91/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.8%)
- BULLISH: Trading 164.0% below Wall St target ($51.71)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$19.79 -
$22.20
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$18.70
Resistance Level
$21.16
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.81
Wall Street Target
$51.71
(+164.0%)
Profit Margin
-199.5%
Share & Embed Analysis
Last updated: October 22, 2026 5:39 PM ET
Data refreshes hourly during market hours. Next update: 6:39 PM
Data refreshes hourly during market hours. Next update: 6:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTHS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 58 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 56 HOLD |
